A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy.

At last follow-up, 5 (50%) patients remained on maintenance lenalidomide, and 5 (50%) patients received a subsequent line of therapy (note: three patients, in the absence of PD, continued on daratumumab beyond the six cycles). It is plausible that in standard-risk patients there may be a stable MRD clone without clinical consequence, leading to clinician and patient preferences to avoid interventions in the absence of a clinical relapse. Despite the improved complete response (CR) rates in multiple myeloma with newer therapies, most patients still relapse [[1]]. Although there was a third patient that converted to bone marrow MRD-negativity, this patient had serologic progressive disease (PD) at the time of response assessment and was deemed not to have achieved the primary end point. [Extracted from the article]